Cargando…
Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes
BACKGROUND: Exogenous insulin antibody syndrome (EIAS) is an immunological disorder caused by circulating insulin antibodies (IAs), featuring hypersensitivity to exogenous insulin and insulin resistance. With the wide use of recombinant human insulin and insulin analogs, there has been a significant...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312206/ https://www.ncbi.nlm.nih.gov/pubmed/37398942 http://dx.doi.org/10.2147/DMSO.S410349 |
_version_ | 1785066895476523008 |
---|---|
author | Han, Chen-Yu Ye, Xiao-Mei Lu, Jia-Ping Jin, Hai-Ying Xu, Wei-Wei Wang, Ping Zhang, Min |
author_facet | Han, Chen-Yu Ye, Xiao-Mei Lu, Jia-Ping Jin, Hai-Ying Xu, Wei-Wei Wang, Ping Zhang, Min |
author_sort | Han, Chen-Yu |
collection | PubMed |
description | BACKGROUND: Exogenous insulin antibody syndrome (EIAS) is an immunological disorder caused by circulating insulin antibodies (IAs), featuring hypersensitivity to exogenous insulin and insulin resistance. With the wide use of recombinant human insulin and insulin analogs, there has been a significant proliferation of EIAS. CASE REPORT: We describe two cases of diabetes mellitus (DM) with hyperinsulinemia and high serum levels of IAs. They had never been exposed to methimazole, glutathione, lipoic acid, and other sulfhydryl drugs, but they all received insulin treatment. The patient in case 1 had recurrent hypoglycemia before hospitalization. A prolonged oral glucose tolerance test (OGTT) showed hypoglycemia with inappropriately high insulin levels. The patient in case 2 was hospitalized for diabetic ketosis. An OGTT indicated hyperglycemia with hyperinsulinemia and low levels of C-peptide. IAs induced by exogenous insulin in the two patients with DM were positive at high titers, prompting a diagnosis of another condition—EIAS. CONCLUSION: We discussed the differences between these two cases of EIAS in clinical manifestations and treatment and summarized all patients of EIAS treated in our department to date. |
format | Online Article Text |
id | pubmed-10312206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-103122062023-07-01 Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes Han, Chen-Yu Ye, Xiao-Mei Lu, Jia-Ping Jin, Hai-Ying Xu, Wei-Wei Wang, Ping Zhang, Min Diabetes Metab Syndr Obes Case Series BACKGROUND: Exogenous insulin antibody syndrome (EIAS) is an immunological disorder caused by circulating insulin antibodies (IAs), featuring hypersensitivity to exogenous insulin and insulin resistance. With the wide use of recombinant human insulin and insulin analogs, there has been a significant proliferation of EIAS. CASE REPORT: We describe two cases of diabetes mellitus (DM) with hyperinsulinemia and high serum levels of IAs. They had never been exposed to methimazole, glutathione, lipoic acid, and other sulfhydryl drugs, but they all received insulin treatment. The patient in case 1 had recurrent hypoglycemia before hospitalization. A prolonged oral glucose tolerance test (OGTT) showed hypoglycemia with inappropriately high insulin levels. The patient in case 2 was hospitalized for diabetic ketosis. An OGTT indicated hyperglycemia with hyperinsulinemia and low levels of C-peptide. IAs induced by exogenous insulin in the two patients with DM were positive at high titers, prompting a diagnosis of another condition—EIAS. CONCLUSION: We discussed the differences between these two cases of EIAS in clinical manifestations and treatment and summarized all patients of EIAS treated in our department to date. Dove 2023-06-26 /pmc/articles/PMC10312206/ /pubmed/37398942 http://dx.doi.org/10.2147/DMSO.S410349 Text en © 2023 Han et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Case Series Han, Chen-Yu Ye, Xiao-Mei Lu, Jia-Ping Jin, Hai-Ying Xu, Wei-Wei Wang, Ping Zhang, Min Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes |
title | Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes |
title_full | Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes |
title_fullStr | Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes |
title_full_unstemmed | Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes |
title_short | Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes |
title_sort | exogenous insulin antibody syndrome in patients with type 2 diabetes |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312206/ https://www.ncbi.nlm.nih.gov/pubmed/37398942 http://dx.doi.org/10.2147/DMSO.S410349 |
work_keys_str_mv | AT hanchenyu exogenousinsulinantibodysyndromeinpatientswithtype2diabetes AT yexiaomei exogenousinsulinantibodysyndromeinpatientswithtype2diabetes AT lujiaping exogenousinsulinantibodysyndromeinpatientswithtype2diabetes AT jinhaiying exogenousinsulinantibodysyndromeinpatientswithtype2diabetes AT xuweiwei exogenousinsulinantibodysyndromeinpatientswithtype2diabetes AT wangping exogenousinsulinantibodysyndromeinpatientswithtype2diabetes AT zhangmin exogenousinsulinantibodysyndromeinpatientswithtype2diabetes |